NCT06235801 2026-06-02A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid LeukemiaM.D. Anderson Cancer CenterPhase 1/2 Recruiting20 enrolled